What is IGF-1 LR3?
IGF-1 LR3 is a modified insulin-like growth factor 1 analog. The Long R3 name refers to an extended N-terminus and an arginine substitution that are intended to reduce binding to IGF-binding proteins and prolong IGF-style signaling in research systems.[1][2][3]
That design makes the molecule biologically interesting, but it also separates it from prescription growth-hormone products and from normal circulating IGF-1 physiology. The key issue is whether this specific analog has route-matched human outcome and safety evidence.[1][2][3]
Product labels often collapse IGF-1, IGF-1 LR3, and research-grade IGF analogs into one category. Those products need separation because potency, binding-protein behavior, exposure, and anti-doping status can differ.[1][2][3] For more context, read the IGF-1 LR3 explainer.
What IGF-1 LR3 is investigated for
IGF-1 LR3 evidence is grouped by practical use case and injectable and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Extended IGF-axis signaling
Injectable
Extended IGF-axis signaling
Injectable
Muscle growth and recovery support
Injectable
Muscle growth and recovery support
Injectable
Evidence snapshot
Overall confidence
IGF-1 LR3 has plausible IGF-axis activity, but controlled human outcome and safety data for this analog are thin. Muscle and recovery evidence remains separate from prescription growth-hormone or native IGF-1 evidence.[1][2][3][6]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
No direct controlled human outcome evidence establishes IGF-1 LR3 for muscle growth, recovery, or body composition. Human relevance is inferred from adjacent IGF-axis literature rather than product-specific results.[1][2][3][6]
Animal / preclinical
Laboratory and animal evidence supports IGF-axis activity and binding-protein differences. Translation to practical injectable outcomes remains uncertain.[1][2][3][6]
Mechanism support
The analog is designed for persistent IGF-1 receptor activity with reduced binding-protein constraint. That mechanism can affect protein synthesis, glucose handling, and cell-survival pathways, which explains both interest and caution.[1][2][3][6]
Forms & administration
IGF-1 LR3 is offered in injectable research-market products. Nasal delivery remains experimental, with animal-only evidence and no established human regimen. Both forms require their own preparation and exposure assessment, separate from prescription IGF-1 medicines.[9][1][2][8]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
What to expect
First 1-2 weeks
Injectable/systemic IGF-axis exposure may show up as fuller training pumps, appetite shifts, body-weight water movement, and glucose-pattern changes.[1][2][3][6][9]
Weeks 4-6
Injectable/systemic recovery, training load, waist, body weight, and lean-mass appearance may settle into a clearer pattern.[1][2][3][6][9]
After stopping
Pump, fullness, and recovery signals may soften after injectable IGF-1 LR3 exposure ends, while training and nutrition determine whether body-composition changes hold.[1][2][3][6][9]
Safety profile
IGF-1 LR3 safety centers on systemic IGF-axis exposure: glucose symptoms, fluid shifts, growth-factor biology, injectable quality, and sport status matter more than ordinary injection comfort.[11]
Common side effects
Cautions
What we don't know
Human dose-response, immunogenicity, long-term metabolic effects, and product interchangeability remain poorly characterized for IGF-1 LR3.[11]
Who IGF-1 LR3 is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Insulin / glucose-lowering drugs
Insulin, sulfonylureas, or other glucose-lowering drugs can intensify or mask glucose symptoms during IGF-axis exposure; this is a GH/insulin-axis caution.[11]
- GH-axis products
Somatropin, GHRPs, or GH secretagogues can stack IGF-axis exposure, edema, and glucose effects; this is a theoretical pathway caution.[11]
- Anabolic hormones
Testosterone, anabolic agents, or strong bulking stacks can compound edema and growth-signal tracking; this is a theoretical pathway caution.[11]
Regulatory status
United States
In the U.S. as of 2026-06-21, IGF-1 LR3 has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket.[9][10][13][14]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved IGF-1 LR3 is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[9][10][13][14] | Not Listed IGF-1 LR3 is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[9][10][13][14] |
Injectable
International
EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[16][17][18][19]
Sports & competition
WADA S2 applies to IGF-1 and related growth-factor activity; tested athletes should not treat injectable IGF-1 LR3 as athlete-cleared without a valid TUE or anti-doping review.[11][9][10][13][14]
How it works
IGF-1 LR3 is an IGF-1 analog designed for longer, less binding-protein-constrained IGF-1 receptor signaling than native IGF-1. That receptor pathway can push protein synthesis, glucose handling, cell survival, and tissue-growth signals, which explains the bodybuilding interest and the endocrine risk.[1][2][3][6]
The route caveat is central because the page is about injectable systemic exposure, not a food supplement or approved replacement product. Persistent IGF-axis signaling can overlap with glucose control, organ-growth, cancer-biology, and anti-doping concerns, so product identity and dose matter more than the shorthand name.[1][2][3][6]
Research gaps & open questions
What the current literature has not yet settled about IGF-1 LR3:
Controlled trials need to study IGF-1 LR3 itself—not standard IGF-1—and show whether it changes muscle growth, fat loss, strength, or recovery in people.[1][2][3][6]
Studies need to show how each route changes exposure and how often IGF-1 LR3 causes low blood sugar or longer-term glucose problems.[1][2][3][6]
Independent testing needs to establish whether research-market products contain authentic IGF-1 LR3 at the labeled strength and are free of important impurities.[1][2][3][6]
Common questions
Is IGF-1 LR3 FDA-approved?
Is IGF-1 LR3 the same as IGF-1?
Myths & misconceptions
Myth
IGF-1 LR3 is just another growth-hormone peptide.
Myth
Longer IGF-style signaling makes it better.
History & discovery
Long R3 IGF-1 entered the literature as a modified IGF-axis research tool, not as a finished medicine. The modification made it useful for studying IGF receptor signaling when ordinary binding proteins complicate interpretation.[1][2][3][6]
Animal and metabolic studies used IGF-1 LR3 to probe protein metabolism, glucose handling, and growth-factor signaling. That shaped later performance-market interest, but it did not create a controlled human muscle-growth program.[1][2][3][6]
Detection work on a black-market Long R3 IGF-I product shifted the story toward identity, purity, and anti-doping concerns. Market visibility therefore became a safety and enforcement issue, not clinical validation.[1][2][3][6]
23 citations
Show citationsHide citations
- [1]IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.Am J Physiol Endocrinol Metab, 2025 Jan 1. animal.
- [2]Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.J Dev Orig Health Dis, 2023 Jun. animal.
- [3]Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers.Domest Anim Endocrinol, 1999 May. animal.
- [4]IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys.J Endocrinol, 1997 Nov. animal.
- [5]Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.J Endocrinol, 1996 Jul. animal.
- [6]Detection of His-tagged Long-R³-IGF-I in a black market product.Growth Horm IGF Res, 2010 Oct. review.
- [7]The somatotropic axis in neonatal calves can be modulated by nutrition, growth hormone, and Long-R3-IGF-I.Am J Physiol, 1997 Jul. animal.
- [8]Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.J Alzheimers Dis, 2025 Jan. animal.
- [9]Drugs@FDA/openFDA query for IGF-1 LR3U.S. Food and Drug Administration. database query.
- [10]Compounding and the FDA: Questions and AnswersU.S. Food and Drug Administration. official guidance.
- [11]The 2026 List of Prohibited Substances and MethodsWorld Anti-Doping Agency. regulatory.
- [12]FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-RegulatedU.S. Food and Drug Administration. official guidance.
- [13]Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration, 2026-05-14. regulatory.
- [14]Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C ActU.S. Food and Drug Administration, 2025-01-07. regulatory.
- [15]Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration, 2026-04-22. regulatory.
- [16]European Medicines Agency medicines searchEuropean Medicines Agency. official guidance.
- [17]MHRA Products searchMedicines and Healthcare products Regulatory Agency. official guidance.
- [18]Drug Product Database: Access the databaseHealth Canada. official guidance.
- [19]Searching the Australian Register of Therapeutic GoodsTherapeutic Goods Administration. official guidance.
- [20]Cosmetic Products RegulationEuropean Commission. official guidance.
- [21]Making cosmetic products available to consumers in Great BritainUK Office for Product Safety and Standards. official guidance.
- [22]Cosmetics regulatory informationHealth Canada. official guidance.
- [23]Cosmetics and soapAustralian Industrial Chemicals Introduction Scheme. official guidance.


